Author: Next Gen Diagnostics

Visit NGD at Booth #712 to learn more about the NGD system, which automates both sample preparation and bioinformatics, as well as generates actionable reports for Infection Prevention teams.

CAMBRIDGE, MA / ACCESS Newswire / October 16, 2025 / Next Gen Diagnostics (NGD) will showcase its new NGD System at ID Week 2025, in Atlanta October 19-22. Attendees can visit Booth #712 to see how NGD’s end-to-end, on-premise service enables hospitals to detect and stop infection transmission in real time.

The NGD System integrates complete robotic sample preparation, sequencing, bioinformatics and HIPAA-compliant root cause determination, all in a streamlined workflow. Come to the booth to learn about the new NGD200, which performs lysis, extraction, normalization, library construction, pooling, and size selection, delivering up to 48 bacterial sequence-ready libraries with no more skill than looping bacterial samples from petri dish to plate. Overnight sequencing, both long- and short-read, is automatically linked to sophisticated, validated, automated bioinformatics, populating an intuitive user interface overnight. NGD’s EpiAssist platform, operating entirely within the hospital’s firewall, identifies root cause and delivers Infection Prevention teams actionable reports identifying outbreaks, root causes, and suggesting opportunities to be considered for intervention.

“We look forward to introducing this system for the first time to Infection Prevention leaders at ID Week,” said Paul A. Rhodes, PhD, CEO and Founder of NGD. “Hospitals are under immense pressure to prevent transmission while managing costs. Our system makes sequence-based transmission detection both affordable and practical by eliminating manual bottlenecks and capital expense.”

What Attendees Will See at Booth #712:

• Walkthroughs of the NGD200 system and EpiAssist analytics interface, showing how transmission reports are generated overnight

• Meet with NGD scientists and engineers

• Learn about system installation, on-premise integration, and hospital workflows

NGD’s turnkey service includes full installation, training (minimal is needed given the low hands-on-time and low skill requirements of the NGD system), and ongoing technical support.

About Next Gen Diagnostics

Next Gen Diagnostics offers an integrated end-to-end sequencing system and bioinformatics service for transmission detection. The proprietary NGD200 instrument can process 48 samples at once, with very low hands-on-time and skill, while fully integrating automated bioinformatics and actionable report generation, all at the low cost-per-sample needed for broad adoption. Please visit nextgen-dx.com for more information.

Based in the US, NGD has a laboratory in Cambridge, MA, with offices in Boston and in Cambridge, UK.

Media Contact:
Samantha Kahn
Director of Strategic Marketing
Next Gen Diagnostics

For press inquiries, please contact: press@nextgen-dx.com

Contact Information

Samantha Kahn
Director of Strategic Marketing
press@nextgen-dx.com

SOURCE: Next Gen Diagnostics

View the original press release on ACCESS Newswire

Move positions company at the heart of Cambridge’s innovation ecosystem to accelerate growth and collaboration in infection prevention.

CAMBRIDGE, MA / ACCESS Newswire / October 14, 2025 / Next Gen Diagnostics (NGD), a biotechnology company delivering automated whole genome sequencing and bioinformatics to track infection transmission in real time, today announced the relocation of its laboratory to Kendall Square in Cambridge, Massachusetts.

The new space, located at the center of one of the world’s most dynamic life sciences hubs, will enable NGD to expand its R&D capabilities, strengthen collaborations with academic and industry partners, and accelerate adoption of its sequencing-based transmission detection technology among hospital systems.

“Kendall Square is synonymous with scientific discovery and collaboration,” said Dr. Paul A. Rhodes, CEO and Founder of Next Gen Diagnostics. “This move places NGD in the middle of a thriving community of innovators and reinforces our commitment to transforming infection prevention through real-time genomics.”

NGD offers a low-cost integrated on-site sequencing and bioinformatic analysis service to bring practical, implementable sequence-based transmission detection to hospital systems. The system automatically generates actionable reports for infection prevention teams delivered via an intuitive user interface, including both transmission-linked patients and probable root cause. IP teams can focus on confirmation of suspected cause and move to the implementation of actions curtailing further transmission, reducing average length of stay while improving patient experience and medical outcome. By closing the detection gap – where over 90% of hospital transmissions currently go unnoticed^1,2 – NGD’s platform empowers healthcare providers to intervene earlier and more effectively.

The relocation underscores NGD’s growth trajectory as it prepares to deepen its U.S. presence and broaden commercialization in 2025.

¹Coll, et al. Science Translational Medicine, 2017
²Sundermann et, al. Clinical Infectious Diseases, 2022

SOURCE: Next Gen Diagnostics

View the original press release on ACCESS Newswire